Figure 6.
COMT as a target to treat GBM. A, The drug treatment and irradiation schedule in mice bearing subcutaneous CT2A tumors. Vehicle and 30 mg/kg entacapone were administered intraperitoneally daily from day 3 to day 35. The tumor-bearing right flank was irradiated on day 10 post tumor cell inoculation. IP, intraperitoneal injection; q.d., every day; IR, irradiation. B, Tumor growth of C57BL/6 mice (n = 6) subcutaneously implanted with 5 × 105 CT2A cells and received entacapone and radiotherapy treatments. C, The treatment schedule of entacapone and a course of fractionated irradiation consisting of five daily doses in the subcutaneous CT2A mouse models. D, Tumor growth of C57BL/6 mice (n = 7) receiving different treatments as shown in C. E, The drug treatment and irradiation schedule in mice bearing intracranial CT2A tumors. Vehicle and 30 mg/kg tolcapone were administered from day 3 to day 35, with a 12-hour interval. Heads of tumor-bearing mice were irradiated on day 9 and day 16 post-tumor engraftment. b.i.d., twice a day. F, Kaplan–Meier survival analysis of mice with intracranial inoculation of 1 × 105 CT2A cells and subsequent treatments as scheduled in E. n = 8 per control group and group with tolcapone monotherapy; n = 15 in groups receiving radiotherapy. P < 0.05 was considered statistically significant; ns, not significant.